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Abstract
The deoxyribonucleic acid (DNA) is the molecule of life that controls all the 
chemical changes that take place in cells. The interaction of drugs with DNA is 
among the most important aspects of biological studies in drug discovery and 
pharmaceutical development processes. Moreover, the knowledge of specific 
targets in rational design of chemotherapeutics is a fundamental factor, princi-
pally, for the design of molecules that can be used in the treatment of oncologic 
diseases. Observing the pre- and postsigns of drug-DNA interaction provides 
good evidence for the interaction mechanism to be elucidated. Also, this inter-
action could be used for the quantification of drugs and for the determination 
of new drugs targeting DNA. Approaches can provide new insight into rational 
drug design and would lead to further understanding of the interaction mecha-
nism between anticancer drugs and DNA. The intention of this chapter is to 
provide several examples of anticancer drugs, DNA interaction, and the mecha-
nisms of interaction in order to understand the influence of several interac-
tion factors in the capacity and selectivity of the anticancer drugs to interact 
with DNA. In addition, different experimental and theoretical approaches to 
detect and to evaluate the anticancer drugs’ interactions with DNA were also 
discussed.
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1. Introduction
DNA information is stored in the form of a code that constitutes four chemical 
bases namely: cytosine (C), adenine (A), thymine (T), and, lastly, guanine (G). 
The human DNA has approximately 3 billion bases, and not <99% of these bases are 
similar in all individuals. The sequence of these bases governs the available infor-
mation for maintaining and building an organism, similar to the manner in which 
alphabetical letters are arranged to form sentences and words [1].
The chemical bases in a DNA pair up (C with G and A with T), in order to 
produce units known as base pairs. In addition, each base is attached to a phos-
phate molecule and a sugar molecule. Together, a phosphate, sugar, and base are 
referred to as a nucleotide. The nucleotides are organized in two long strands 
thereby forming a spiral known as a double helix. A double helix’s structure 
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resembles a ladder, with the phosphate and sugar molecules forming the lad-
der’s vertical sidepieces. On the other hand, the base pairs form the rungs of the 
ladder.
Many anticancer drugs in clinical use interact with DNA through intercala-
tion, which can be defined as the process by which compounds containing planar 
aromatic or heteroaromatic ring systems are inserted between adjacent base pairs 
perpendicularly to the axis of the helix and without disturbing the overall stacking 
pattern due to Watson-Crick hydrogen bonding [2, 3].
2. Structural features of DNA
DNA consists of two complementary anti-parallel sugar phosphate poly-deoxy-
ribonucleotide strands that are associated with specific hydrogen bonding between 
nucleotide bases. The two strands are held together primarily through Watson-
Crick hydrogen bonds where A forms two hydrogen bonds with T and C forms three 
hydrogen bonds with G (Figure 1). The structure of these paired strands defines the 
helical grooves, within which the edges of the heterocyclic bases are exposed. The 
biologically relevant B-form of the DNA double helix is characterized by a shallow-
wide major groove and a deep-narrow minor groove. The chemical structure 
(feature) of the molecular surfaces in a given DNA sequence is well known in either 
groove. This forms the basis for molecular recognition of duplex DNA by small 
molecules and proteins [4, 5].
Figure 1. 
Watson-Crick pairing between purine and pyrimidine bases in complementary DNA strand.
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3. Anticancer drug-DNA interaction
DNA as carrier of genetic information is a major target for anticancer drug inter-
action because of the ability to interfere with transcription and DNA replication, a 
major step in cell growth and division. There are three principally different ways of 
anticancer drug binding. First is through control of transcription factors and polymer-
ases. Here, the anticancer drugs interact with the proteins that bind directly to DNA. 
Second is through RNA binding to DNA double helices to form nucleic acid triple 
helical structures or RNA hybridization to exposed DNA single strand regions that 
will be forming DNA-RNA hybrids and it may interfere with transcriptional activity. 
Third is through small aromatic ligand molecules that bind to DNA double helical 
structures through non-covalent interaction either by intercalating binder or by minor 
groove binders (Figure 2) [6, 7]. Therefore, intercalation can be defined as the process 
by which compounds containing planar aromatic or heteroaromatic ring systems are 
inserted between adjacent base pairs perpendicularly to the axis of the helix and with-
out disturbing the overall stacking pattern due to Watson-Crick hydrogen bonding [8]. 
In addition, intercalation binding involves the insertion of a planar molecule between 
DNA base pairs, which results in a decrease in the DNA helical twist and lengthening 
of the DNA. While groove binding, unlike intercalation, does not induce large con-
formational changes in DNA and may be considered similar to standard lock-and-key 
models for ligand-macromolecular binding. In addition, Groove binders are usually 
crescent-shaped molecules that bind to the minor groove of DNA [7].
In order to accommodate the binder (like intercalation binder), DNA must 
undergo a conformational change to create a cavity for the incoming chromophore. 
The double helix is therefore partially unwound, which leads to distortions of the 
sugar-phosphate backbone and changes in the twist angle between successive base 
pairs (Figure 3) [8]. Once the drug has been sandwiched between the DNA base 
Figure 2. 
Groove binding to the minor groove of DNA (left) and the intercalation into DNA (right).
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pairs, several non-covalent interactions such as Van der Waals interaction and 
hydrogen bonding optimizes the stability of the complex.
4. Types of drug-DNA interactions
The study of interaction between drug molecules and DNA is very exciting and 
significant not only in understanding the mechanism of interaction, but also for 
the design of new drugs. However, the mechanism of interactions between them 
is still relatively little known. By understanding the mechanism of interaction 
between them, designing of new DNA-targeted drugs and the screening of these 
in vitro will be possible [9]. Many of the most valuable anticancer drugs currently 
used in therapy interact with DNA either by a covalent or non-covalent mechanism. 
Unfortunately, several of them show a considerable toxicity when the DNA molecu-
lar target is present in both normal and tumor cells [10]. The covalent type of bind-
ing of drug-DNA is irreversible and invariably causes the complete inhibition of 
DNA processes and subsequent cell death. A major advantage of covalent binders is 
the high binding strength. However, covalent bulky adducts can cause DNA back-
bone distortion, which affect both transcription and replication (disrupting protein 
complex recruitment). The covalent binders are also called alkylating agents due to 
adduct formation because they are used in cancer treatment to attach an alkyl group 
(CnH2n+1) to DNA [11]. Table 1 lists the different types of drug-DNA interactions 
with suitable examples. In addition, some important examples of a cross-linking 
agent covalent and non-covalent binder were shown in Figure 4 [5, 12].
Figure 3. 
Deformation of DNA by an intercalating agent.
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Non-covalent DNA interacting agents (groove, intercalators, and external bind-
ers) are generally considered less cytotoxic than agents producing covalent DNA 
adducts and other DNA damage. The non-covalent binding type is reversible and 
is typically preferred over covalent adduct formation keeping the drug metabolism 
and toxic side effects in mind. In addition, non-covalent DNA interacting agents 
can changes DNA conformation, DNA torsional tension, interrupt protein-DNA 
interaction, and potentially lead to DNA strand breaks [11].
5. Modeling of hairpin minor groove binders
Hairpin minor grove binding molecules have been identified and synthesized 
that bind to G-C reach nucleotide sequences. Hairpin polyamides are linked systems 
that exploit a set of simple recognition rules for DNA base pairs through specific 
orientation of imidazole (Im) and pyrrole (Py) rings (Figure 5) [13]. They origi-
nated from the discovery of the three-ring Im-Py-Py molecule that bound to minor 
groove DNA as an antiparallel side by side dimer.
The solid phase synthesis of polyamides of variable length has produced effi-
cient ligands. The advantage of polyamide ligand design has been reached with 
finding structures able to recognize DNA sequences of specific genes. Moreover, 
a new strategy of rational drug design exploits the combination of polyamides 
with bis-intercalating structures. The new synthetic compound showed a resistant 
against multidrug resistance in which small aromatic compounds are efficiently 
No. Type of interaction Example
1 Covalent bonding Nitrogen mustard, carboplatin and cyclophosphamide
2 Non-covalent bonding Ethidium bromide and quinacrine
Table 1. 
Listing the different types of drug-DNA interactions with suitable examples.
Figure 4. 
Chemical structure of some covalent and non-covalent binders of DNA.
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expelled from the cell-by-cell membrane transport proteins that commonly referred 
to as ABC transporters or ATP binding cassette proteins [14].
6. Rational for drug design
When a compound intercalates into nucleic acids, there are changes, which 
occur in both the DNA and the compound during complex formation that can be 
used to study the ligand DNA interaction. The binding is of course an equilibrium 
process because no covalent bond formation is involved. The binding constant can 
be determined by measuring the free and DNA bound form of the ligand. In addi-
tion, DNA double helix structures are found to be more stable with intercalating 
agents present and show a reduced heat denaturation. Correlating these biophysical 
parameters with cytotoxicity is used to support the antitumor activity of these 
drugs as based on their ability to intercalate in DNA double helical structures. [15].
Improvement of anticancer drugs based on intercalating activity is not only 
focused on DNA-ligand interaction, but also on tissue distribution and toxic side 
effects on the heart (cardiac toxicity) due to redox reduction of the aromatic rings 
and subsequent free radical formation. Free radical species are thought to induce 
destructive cellular events such as enzyme inactivation, DNA strand cleavage and 
membrane lipid peroxidation [16, 17].
7. Cisplatin-DNA interactions
Cisplatin (cis-[PtCl2(NH3)2]) is the most widely used anticancer drug today. 
Since the development of cisplatin became one of the main biological targets for 
the antitumor compounds. It is used against ovarian, cervical, head and neck, 
esophageal and non-small cell lung cancer. However, chemotherapy treatment by 
cisplatin comes with a price of severe side effects including nausea, vomiting and 
ear damage, as cisplatin not only attacks cancer cells, but also healthy cells. It is 
therefore important to elucidate the details of the cisplatin mode of action to design 
new cisplatin analogs that specifically target cancer cells. Furthermore, most cancer 
cells are insensitive towards cisplatin or develop resistance. There is therefore, also 
a need for cisplatin analogues with a broader range of cytotoxicity. The search for 
new analogues and the elucidation of the complete mode of action have been going 
on for more than 40 years and there is an enormous amount of data available for 
researchers. Still, the picture of how cisplatin works is incomplete [11, 18].
Figure 5. 
Structure of hairpin polyamide Im-Py-Py.
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Cellular DNA has been shown to be the primary target for cisplatin, 
although cisplatin can react with several other cellular components. In the cell, 
the salt concentration is significantly lower (~20 mM) and cis-[PtCl2(NH3)2] 
is hydrolyzed by high salt concentration (>100 mM) to the probable active 
species cis-[PtCl(OH2)(NH3)2]
+. The hydrolyzed product binds to DNA and 
preferentially to guanine N7> > adenine N7 > cytosine N3, first as a monoad-
duct, then forming a bidentate adduct. The primary products are 1,2-intra-
strand cross-links of GpG (60–65%) or ApG (20–25%) sequences. A smaller 
amount corresponds to 1,3-intrastrand or G N7–G N7 interstrand adducts. The 
most common binding sites on the nucleobases for Pt are shown in Figure 6 
[18]. The big arrow on guanine indicates the overall favorable coordination 
site in DNA, the arrow towards thymine is dotted because the proton has to be 
removed before Pt association.
The formation of these 1,2-intrastrand cross-links alters the duplex conforma-
tion. The most dramatic effect is unwinding of the two strands and bending of 
the DNA double helix (several values for the bend angle are reported in the range 
20–80°). The platinated adducts are assumed to be recognized by proteins, fol-
lowed either by stabilization of the distorted DNA structure or removal of the 
lesion through repair [18]. The deformation of the DNA structure can interfere 
with the normal functions of DNA, such as replication and transcription, leading to 
cellular death by apoptosis or necrosis. The ineffective isomer of cisplatin, trans-
platin (trans-[PtCl2(NH3)2]), is not able to form 1,2-intrastrand cross-links [19]. 
Transplatin forms only 1,3-intrastrand and interstrand cross-links and this might be 
the reason why transplatin is antitumor inactive [18].
In addition, a sensing system based on the photoinduced electron transfer of 
quantum dots (QDs) was also designed to measure the interaction of anticancer 
drug and DNA, taking mitoxantrone (MTX) as a model drug. The MTX adsorbed 
on the surface of QDs and this, can quench the photoluminescence (PL) of QDs 
through the photoinduced electron-transfer process, then the addition of DNA will 
bring the restoration of QDs PL intensity, as DNA can bind with MTX and remove 
it from QDs.
Figure 6. 
The structure of the most common binding sites on the nucleobases for Pt. The big arrow on guanine indicates 
the overall favorable coordination site in DNA, the arrow towards thymine is dotted because the proton has to 
be removed before Pt association.
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Cisplatin-DNA sequence selectivity has been given great attention from the research 
community. Several studies show that cisplatin first binds monofunctionally to guanine 
N7 and is particularly reactive towards Gn-runs (n ≥ 2) (Figure 7) [18, 20, 21]. The high 
nucleophilicity of Gn-runs attracts the positively charged cisplatin monoaqua specie. 
The lifetime of the monoadduct is relatively long and it has therefore been suggested 
that the initial monoadduct is crucial for the type of cross-linked adduct formed and 
thus for the cytotoxic properties of the Pt complex. The main factors influencing the 
mono-functional binding affinity in DNA are thought to be [18] the type of bound 
nucleotide and of the adjacent residues, the steric effects of the Pt complex, the hydro-
gen binding properties of the Pt-DNA adduct and the DNA conformation.
8. Sequence specific structural perturbation
The formation of a cisplatin adduct with the GpG bases requires a significant tilt-
ing of the bases leading to a perturbation of the regular B-DNA conformation. The 
structural perturbation has been shown to be specifically recognized by a number 
of cellular proteins, including proteins with high-mobility group (HMG) binding 
domains and the TATA box binding protein [22]. It is believed that (some of) these 
recognition proteins mediate the cellular response which finally induces cell death by 
apoptosis or necrosis. In some cases, relatively subtle changes in the adduct structure 
can affect the recognition and the biological effects in a major way. This is exempli-
fied by the cisplatin analogue oxaliplatin which forms similar G*G*-Pt adducts as 
cisplatin [18]. However, the oxaliplatin-G*G adducts differ in repair efficiency, 
mutagenesis and translesion synthesis, believed to be related to the differential 
activity of the two drugs (oxaliplatin is used, in combination with 5-fluorouracil, for 
the treatment of colorectal cancers against which cisplatin is inactive). The evalu-
ation of the structural details of the platinum-DNA adducts and of their effects on 
protein, recognition can therefore help to understand why the biological activities of 
two similar platinum compounds (e.g., cisplatin versus oxaliplatin) are different. So 
far only nine cisplatin-DNA adducts have been characterized by NMR and/or x-ray 
crystallography. These structures were extensively reviewed by Ano et al. and found 
to be basically similar in structure. The cisplatin-GG adduct kinks the double helix 
approx. Approximately 60 towards the major groove and induces N sugar pucker for 
X of 5′ XG*, 5′ G* and the C complementary to 3′ G* [18].
Figure 7. 
Assumed mechanism for the formation of cisplatin-DNA adducts.
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This metal-based compound or coordination compounds that bind to DNA have 
been an active area of research since the discovery of cisplatin and the platinum-based 
drugs. The transition-metal compounds bind to DNA through several ways and differ-
ent factors that promote it, such as the intercalant ligand and the nature and position 
of the substituent over it. Several techniques to follow metal-based drugs interactions 
with DNA are used as a powerful tool in order to reach a deep knowledge of the param-
eters involved in the stabilization of coordination compound-DNA adduct.
9. Methods for elucidation of DNA-anticancer drug interactions
DNA damaging agents (drugs that interfere with DNA function by chemically 
modifying specific nucleotides) includes mitomycin-C and echinomycin.
9.1 Mitomycin-C
Mitomycin-C is a well-characterized antitumor antibiotic that forms a covalent 
interaction with DNA after reductive activation (Figure 8). The activated antibiotic 
forms a cross-linking structure between guanine bases on adjacent strands of DNA 
therefore inhibiting single strand formation [8].
9.2 Echinomycin
Several studies have proved that both echinomycin quinoxaline rings bisinterca-
late into DNA, with CG selectivity, while the inner part of the depsipeptide estab-
lishes H-bonds with the DNA bases of the minor groove region of the two base pairs 
comprised between the chromophores (Figure 9) [8].
Figure 8. 
Schematic interaction between DNA and mitomycin-C.
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10. Mechanisms of anticancer drug-DNA interaction
The addition of anticancer drugs to a DNA molecule creates a new bond. Some 
examples for these mechanisms include intercalating agents, intercalating reagents 
(II), and bleomycins.
10.1 Intercalating agent
This agent contains planar aromatic or heteroaromatic ring systems (dactinomycin 
as an example), binding to sugar phosphate backbone by cyclic peptide or by NH3. 
The planar systems slip between the layers of nucleic acid pairs and disrupt the shape 
of the helix. The preference is often shown for the minor or major groove. The inter-
calation prevents replication and transcription. In addition, the intercalation inhibits 
Figure 10. 
Diagrammatic model illustrating intercalation of the flat part of the molecule of adriamycin (in black) into 
DNA, presenting the local unwinding of the helical structure.
Figure 9. 
Schematic interaction between DNA and echinomycin.
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topoisomerase II (an enzyme that relieves the strain in the DNA helix by temporarily 
cleaving the DNA chain and crossing an intact strand through the broken strand). 
Another example is the intercalation of the flat part of the molecule of Adriamycin 
into DNA, presenting the local unwinding of the helical structure (Figure 10) [23].
10.2 Intercalating reagents (II)
During replication, supercoiled DNA is unwound by the helicase. The thereby 
created tension is removed by the topoisomerase II (topo II) that cuts and rejoins the 
DNA strands. When doxorubicin is bound to the DNA it stabilizes the DNA-topo (II) 
complex at the point where the enzyme is covalently bound (Figure 11) [1, 24].
Figure 11. 
Stabilizations of DNA-topo (II) complex.
Figure 12. 
The intercalating region (in blue color) of bleomycin A2 via the bithiazole moiety to DNA.
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10.3 Bleomycin A2
The bleomycin A2 intercalate via the bithiazole moiety (DNA-binding domain) 
(Figure 12). The bithiazole moiety intercalates into the double helix and the attached 
side chain containing a sulfonium ion is attracted to the phosphodiester backbone. 
In addition, the N-atoms of the primary amines, pyrimidine ring and imidazole ring 
chelate Fe, which is involved in the formation of superoxide radicals, which subse-
quently act to cut DNA between purine and pyrimidine nucleotides [25].
11. Techniques for studying drug-DNA interactions
Various analytical techniques have been used for studying drug-DNA interac-
tions (interaction between DNA and small ligand molecules that are potentially 
of pharmaceutical importance). Several instrumental techniques (emission and 
absorption spectroscopic) such as infrared (IR), UV-visible, nuclear magnetic 
resonance (NMR) spectroscopies, circular dichroism, atomic force microscopy 
(AFM), electrophoresis, mass spectrometry, viscosity measurements (viscometry), 
UV thermal denaturation studies, and cyclic, square wave and differential pulse 
voltammetry, etc., were used to study such interactions. These techniques have been 
used as a major tool to characterize the nature of drug-DNA complexation and the 
effects of such interaction on the structure of DNA. In addition, these techniques 
are regularly applied to monitor interactions of drugs with DNA because these 
optical properties are easily measured and tend to be quite sensitive to the environ-
ment. Moreover, these techniques provide various types of information (qualitative 
or quantitative) and at the same time complement each other to provide full picture 
of drug-DNA interaction and aid in the development of new drugs. In addition, the 
information gained from this part might be useful for the development of potential 
survey for DNA structure and new therapeutic reagents for tumors and other 
diseases. In this part of the chapter, we will focus on FT-IR, UV-Visible, NMR, AFM 
and viscosity measurements [5].
11.1 Fourier transform infrared spectroscopy
Fourier transform infrared (FT-IR) spectroscopy is a widely used technique to 
study interactions of nucleic acids (DNA and RNA) and proteins with anticancer 
drugs and other cytotoxic agents in solutions [26, 27]. In addition, it can generate 
structural information of the whole molecule in a single spectrum as a photograph 
of all conformations present in the sample that can distinguish among A-, B- and 
Z-forms of DNA, triple stranded helices, and other structural patterns. In addition, 
it is a powerful tool to study interactions of DNA with drugs and the effects of such 
interactions in the structure of DNA, and providing some insights about the mecha-
nism of drug action. The technique is ideal for systematic studies of nucleic acids 
(e.g., sequence variations, covalent modifications), since it is fast, nondestructive, 
and requires only small amount of sample [28].
IR spectrum can be divided into four characteristic spectral ranges. The region 
between 1800 and 1550 cm−1 corresponds to the in-plane double bond vibrations of 
the nucleic bases (C〓O, C〓N, C〓C and N▬H bending vibrations of bases). These 
bands are sensitive to changes in the base stacking and base pairing interactions. 
Bands occurring in the interval 1500–1250 cm−1 assigned to vibrations of the bases 
and base-sugar connections are strongly related to the conformational changes of the 
backbone chain and glycosidic bond rotation. The range 1250–1000 cm−1 involves 
sugar phosphate vibrations, such as, PO2 symmetric and asymmetric stretching 
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vibrations and C▬O stretching vibrations. These vibrations show high sensitivity to 
conformational changes in the backbone. The range 1000–800 cm−1 is characteristic 
for bands associated with vibrations of sugars which correlate with the various 
nucleic acid sugar puckering modes (C2’-endo and C3’-endo) [29, 30].
Due to interfering absorption bands of water at 1650 cm−1 and below 
950 cm−1, spectra are generally recorded also in D2O, where these bands move to 
1200 cm−1, and below 750 cm−1. Combination of results from both spectra allows 
obtaining a complete spectrum. The use of D2O also causes shifts in nucleic 
acid absorptions, resulting from deuterium exchange of labile NH protons, and 
these can be used to monitor H–D exchange processes. A method to remove 
water signals in the spectra is water subtraction, using a sodium chloride (NaCl) 
solution as reference. D2O is used to allow shifts in the absorption of nucleic acid 
in order to monitor H–D exchange processes. Four regions, each having marker 
bands showing either nucleic acid interactions or conformations, are presented 
in Figure 13 [31, 32].
The ring vibrations of nitrogenous bases (C〓O, C〓N stretching), PO2 stretch-
ing vibrations (symmetric and asymmetric) and deoxyribose stretching of DNA 
backbone are confined in the spectral region between 1800 and 700 cm−1. The 
vibrational bands of DNA at 1710, 1662, 1613 and 1492 cm−1 are assigned to guanine 
(G), thymine (T), adenine (A) and cytosine (C) nitrogenous bases, respectively. 
Bands at 1228 and 1087 cm−1 denote phosphate asymmetric and symmetric 
vibrations, respectively. These are the prominent bands of pure DNA, which are 
monitored during carboplatin-DNA interaction at different ratios. Changes in these 
bands are shown in Figure 14 [33]. After carboplatin addition to DNA solution, 
G-band at 1710 shifts to 1702–3, T-band at 1662 shifts to 1655 and A-band at 1613 
shifts towards lower wave number 1609–10 cm−1. These shifting can be attributed 
to direct platin binding to G (N7), T (O2), and A (N7) of DNA bases. No major 
shifting is observed for phosphate asymmetric and symmetric vibrations indicating 
no external binding. The plots of the relative intensity (R i) of several peaks of DNA 
in-plane vibrations related to A–T, G–C base pairs and the PO2
− stretching vibra-
tions such as 1717 (G), 1663 (T), 1609 (A), 1492 (C), and 1222 cm−1 (PO2
− groups), 
against the compound concentrations can be obtained after peak normalization 
using formula (1) [5, 34]:
  Ri =  
I i ____ 
l 968
(1)
where Ri is the relative intensity, Ii is the intensity of absorption peak for pure 
DNA and DNA in the complex with i concentration of compound, and l968 is the 
intensity of the 968 cm−1 peak (internal reference) [35].
Figure 13. 
The characteristics IR bands of DNA and aqueous solvents. (a) 1800–1500 cm-1 region is sensitive to effects of 
base pairing and base stacking; (b) 1500–1250 cm-1 region is sensitive to glycosidic bond rotation, backbone 
conformation, and sugar pucker; (c) 1250–1000 cm-1 region is sensitive to backbone conformation; and  
(d) 1000–800 cm-1 region is sensitive to sugar conformation.
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Similarly, Raman spectroscopy, which also depends on characteristic group 
vibrational frequencies, can be used together with infrared spectra to study vibra-
tions in DNA. It is useful because Raman and IR spectroscopy provide complemen-
tary information.
11.2 UV-visible spectroscopy
UV-visible absorption spectroscopy can be utilized to detect the DNA-ligand 
interaction by measuring the changes in the absorption properties of the DNA 
molecules or the ligand. The UV-vis absorption spectrum of DNA displays a broad 
band in the range of 200–350 nm in the UV region, with a maximum situated at 
260 nm. The maximum is due to the chromophoric groups in pyrimidine and purine 
moieties responsible for the electronic transitions. The utilization of this simple and 
versatile technique enables an accurate estimation of the DNA molar concentration 
based on absorbance measurement at 260 nm. To measure the interaction between 
ligands and DNA, a hypochromic shift is utilized because the monitoring of the 
values of absorbance enables studying of the melting action of DNA. Apart from 
versatility, other major advantages of UV-vis absorption spectroscopy include 
simplicity, reproducibility, and good sensitivity [36, 37].
11.3 Nuclear magnetic resonance spectroscopy
Binding between ligands and the molecules of DNA causes a significant change 
in the chemical shift of the values presented in Table 2 [32]. For example, applying 
thermal denaturing in order to un-stack the base-pair double-helical DNA to form 
two ss-DNAs is often accompanied by the 1H resonances’ downfield shift for non-
exchangeable protons.
The broadening of 1H NMR resonances of DNA upon addition of an appropriate 
minor groove binding compound is one type of evidence of complex formation in 
DNA 31P-NMR spectroscopy has also been used to provide important information 
concerning the binding of intercalators to DNA. The 31P chemical shifts are sensi-
tive DNA conformational changes, and hence intercalating drugs cause downfield 
shift, while divalent cations causes up field shifts in the 31P signal [38].
Figure 14. 
Intensity ratio variations for DNA as a function of different carboplatin/DNA molar ratios.
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11.4 Mass spectrometry
Mass spectrometry (MS) has become one of the most common techniques adopted 
to study interactions between DNA and small ligand molecules. The ability of mass 
spectrometry to investigate drug-DNA interactions have been reviewed recently. The 
binding stoichiometry, the relative binding affinities and the binding constants for 
DNA double helices of various sequences may be determined. Electrospray ionization 
(ESI) is the most common ionization method used in the study of biomolecules due 
to its soft ionization. Using ESI techniques, biomolecules can be transferred from the 
solution to the mass spectrometer with minimal fragmentation and, so, both the mass 
of the DNA and the mass of the DNA-ligand complex can be determined, as the non-
covalent interactions that formed the complex are not altered during the electrospray 
process [39–41]. Focusing on the use of ESI-MS to study complexes, MS gives a signal 
for each species with a different mass and so it is very straightforward to establish 
the stoichiometry of the complexes. ESI-MS signals enable several calculations to be 
performed. The number of DNA strands involved, the number of bound cations (if 
present) and the number of bound ligands, among others. Taking into account the 
structure of the nucleic acids, ESI-MS studies are performed using negative polarity. It 
is well known that the phosphodiester backbone of DNA is fully deprotonated under 
usual working conditions. In general, in order to preserve their structure, nucleic acid 
solutions are prepared with monovalent ions. Perylene derivatives, such as, N,N-
bis-(2-(dimethylamino)ethyl)-3,4,9,10-perylenetetracarboxylic acid diimide, favor 
π-π interactions with the G-tetrad surface. Moreover, 5,10,15,20-tetrakis-(1-methyl-
4-pyridyl)-21H,23H-porphine is an effective telomerase inhibitor, also binds to the 
G-quadruplex in the c-myc promoter [42].
11.5 Atomic force microscopy
Atomic force microscopy (AFM) can be used to distinguish proteins bound to 
nucleic acid templates. One of the great advantages of the atomic force microscope, 
particularly with respect to the imaging of biological specimens, is that it can work 
in fluid, so that experiments can be performed under near physiological conditions 
and allowing the imaging of interactions and transactions between molecules 
in real time [43]. AFM techniques will play a larger role in studying interactions 
between biological specimens, such as ligand-receptor and protein-DNA systems, 
Proton type Expected chemical 
shifta (ppm)
Proton type Expected chemical 
shifta (ppm)
T5 (CH3) 1.00–2.00 A 2 (CH); A 8 (CH); G 8 (CH) T 6 
(CH) C 6 (CH)
6.50–8.20
Sugar 2′ (CH2) 2.00–3.00
Sugar 5′ terminal 
(CH2)
3.70
Sugar 5′ (CH2); 
4’(CH)
4.00–4.50 C 4 (NH2) (H-1)
b 6.40–6.80
Sugar 3′ (CH) 4.50–5.20 C 4 (NH2) (H-2)
b 8.30–8.50 ppm
Sugar 1′ (CH) 5.30–6.20 G 1 (NH) 12.50–13.00 ppm
C 5 (CH) 5.30–6.20 T 3 (NH) 13.50–14.00 ppm
a Chemical shifts relative to internal TSP (3-(trimethylsilyl)propionic acid). 
b For Watson-Crick base pairs (CG).
Table 2. 
Typical ranges of chemical shifts for 1H NMR spectra of nucleic acids.
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and can be applied to the study of drug interactions with a variety of biological 
specimens [5].
Drug-DNA complexes have been studied with AFM to determine the binding 
force between them. This is of considerable interest since nucleic acid ligands 
are commonly used as anticancer drugs and in the treatment of genetic diseases. 
However, determining whether they bind to DNA by intercalation within major 
and/or minor grooves, by normal modes, or by a combination of these modes can 
often be difficult. AFM was used to study drug binding mode, affinity, and exclu-
sion number by comparing the length of DNA fragments that have and have not 
been exposed to the drug. It is well known that if intercalative binding is occurring, 
the DNA strand increases in length. Moreover, the degree of lengthening is infor-
mative in determining the binding affinity and the site-exclusion number. AFM 
was shown to be an effective means of seeing and measuring any changes in the 
DNA strand. For example, when it exposed to ethidium, the DNA strand was shown 
through AFM to have increased in length from 3300 to 5250 nm, this indicating the 
intercalative mode of binding. Similarly, AFM intercalative binding studies showed 
the increase in the DNA strand, from 3300 to 4670 nm, upon exposure to dauno-
mycin. This technique has also successfully been applied to new drugs in which the 
mode of binding was unclear. For example, exposure of 2,5-bis(4-amidinophenyl) 
(APF), did not produce lengthening of the DNA strands, indicating that the drug 
binds by non-intercalative modes. The different structural changes and binding 
processes of the DNA occur because of interactions with these two components [5].
11.6 Viscosity measurements
DNA viscosity is sensitive to DNA length change, for this reason, its measure-
ment upon the addition of a compound is often concerned as the least ambiguous 
and most critical method to clarify the interaction mode of a compound with 
DNA and this will provide reliable evidence for the intercalative binding mode. 
Relative viscosity measurements have proved to be a reliable method for the 
assignment of the mode of binding compounds to DNA. In the case of classical 
intercalation, DNA base pairs are separated in order to host the bound compound 
resulting in the lengthening of the DNA helix and subsequently increased DNA 
viscosity. On the other side, the binding of a compound exclusively in DNA 
grooves by means of partial and/or non-classic intercalation, under same condi-
tions, causes a bend or kink in the DNA helix and reducing its effective length 
and, as a result, DNA solution viscosity is decreased, or it remains unchanged.
Figure 15 show the interaction of three Schiff base compounds of 
N′-substituted benzohydrazide and sulfonohydrazide derivatives: (1) N′-(2-
hydroxy-3-methoxybenzylidene)-4-tert-butylbenzohydrazide, (2) N′-(5-bromo-2 
hydroxy-benzylidene)-4-tert-butylbenzohydrazide and (3) N′-(2-hydroxy-3-
methoxy-benzylide-ne)-4-methylbenzenesulfonohydrazide with SS-DNA [44]. 
This can be explained by the insertion of the compounds in between the DNA base 
pairs, leading to an increase in the separation of base pairs at intercalation sites and, 
thus, an increase in DNA length [45].
The viscosity data show that there are at least two phases of binding between the 
complex and CT-DNA. At lower concentration of the complex, the viscosity first 
decreases and then increases at higher concentration of complex. This slow increase 
in viscosity is an indication of groove binding [11].
Figure 16 indicate that with increasing amount of (3-(3,5 dimethyl-phenylimino)
methyl)benzene-1,2-diol (HL), the relative viscosity of DNA first remains con-
stant and then increases [46]. This observation supports that HL bind through 
intercalation mode but with different affinity, i.e., also show some affinity for 
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binding with grooves of DNA through hydrogen bonding, typically to N3 of 
adenine and O2 of thymine. However, strong binding is presumably due to interca-
lation with DNA [11].
Figure 15. 
Effects of increasing amount of compounds (1–3) on relative viscosity of SS-DNA at 25 ± 0.1°C. 
[DNA] = 7.2 μM, r = 0, 6.9, 13.9, 20.8, 27.8.
Figure 16. 
Effects of increasing amount of HL on relative viscosity of CT-DNA at 25 ± 0.1°C. [DNA] = 2.37 × 10−5 M.
Figure 17. 
(1) Effect of increasing amount of the complexes [Ni(hhmh)2], (2) [Ni(bhmh)2], (3) [Ni(ihmh)2], (4) [Ni(PPh3)
(hpeh)], (5) [Ni(PPh3)(bpeh)] and (6) [Ni(PPh3)(ipeh)] on the relative viscosity of HS-DNA at 16(±0.L)°C.
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Figure 17 [47] and Figure 18 [48] shows the electrostatic binding mode of 
nickel and organotin(IV) complexes with DNA, respectively. The viscosity of DNA 
remains essentially unchanged on the addition of the nickel complexes while it 
decreases in case of organotin(IV) complexes [11].
12. Conclusions
This chapter has focused on drug-DNA interactions and their study by various 
analytical techniques such as IR spectroscopy, viscosity measurements, MS and 
AFM. These techniques are used to evaluate the binding mode as well as binding 
strength of the complex formed between drug and DNA. The study should be 
useful for the development of potential survey for DNA structure and new thera-
peutic reagents for tumors and other diseases. Fundamentally, drugs interact with 
DNA through two different ways, covalent and/or non-covalent modes. Covalent 
binders act as alkylating agents as they alkylate the nucleotides of DNA, while, the 
non-covalent binders interact by three different ways: (i) intercalation, (ii) groove 
binding, and (iii) external binding (on the outside of the helix). Different spectro-
scopic techniques are generally, powerful tools to study interactions of DNA with 
drugs and the effects of such interactions in the structure of DNA, providing some 
insights about the mechanism of drug action. The binding stoichiometry, the rela-
tive binding affinities and the binding constants for DNA double helices of various 
sequences.
Figure 18. 
(1) Effects of increasing amount of tri-n-butyltin (IV) 3-[(3′,5’dimethylphenylamino)] propanoate and  
(2) triphenyltin(IV) 3-[(3′,5’dimethylphenylamino)]propanoate on relative viscosity of SS-DNA at 25 ± 0.1°C, 
[DNA] = 1.86 × 10−4 M.
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